Rhythm Pharmaceuticals Inc (STU:1RV)
€ 38.705 0.845 (2.23%) Market Cap: 2.43 Bil Enterprise Value: 2.24 Bil PE Ratio: 0 PB Ratio: 41.42 GF Score: 52/100

Rhythm Pharmaceuticals, Inc. - Special Call Transcript

Sep 25, 2019 / 12:15PM GMT
Release Date Price: €21.67 (+2.31%)
Hunter C. Smith
Rhythm Pharmaceuticals, Inc. - CFO & Treasurer

Good morning. Thanks, everyone, for coming. And we really appreciate you joining this Rhythm R&D Event. I'm Hunter Smith, Chief Financial Officer of Rhythm, and we have a lot of ground to cover this morning, so let's jump right in. I need my clicker, I'm sorry. Please review the forward-looking statements available with these slides and in our press release this morning.

Today, we've got a group of speakers that are really some of our -- the core of the Rhythm management team is here. First, Dr. Gottesdiener. Keith, who you all know, he's been our CEO and Director of the company since 2011. He joined Rhythm after a 16-year career at Merck Research Labs, where he led Merck's early clinical development across all therapeutic areas from 2001 to 2006. From 2006 to 2011, he was leader of Merck's late clinical development organization, first overseeing the development of Merck's infectious diseases and vaccine products through pivotal trial, registration, and life-cycle management, including GARDASIL and many others. He received a

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot